Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2090314 + Chemotherapy in Metastatic Pancreatic Cancer
NCT01632306Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY2090314, sponsored by Eli Lilly and Company. Started Mar 2013; status: terminated.
02
Drugs
LY2090314
Beyond the preview
Go deeper on NCT01632306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632306.